[Continuous treatment with colony stimulating factors (G-CSF) for neutropenia associated with type Ib glycogenosis].
In the last few years, granulocyte colony stimulating factors (G-CSF), or hematopoietic growth factors, have created new possibilities for treating severe neutropenias, with high clinical efficacy and minimal adverse effects. Moreover, due to genetic recombinant techniques, the therapeutic use of these glycoproteins is increasing. We report the case of a 4-year-old girl who was diagnosed with glycogenosis IB at the age of 7 months. From the age of 2 years, she presented severe established neutropenia secondary to the main disease. Subcutaneus G-CSF therapy was started. The patient has shown no serious infections, has maintained normal growth and development, and has not required hospitalization. Adverse effects have been minimal. The therapeutic efficacy demonstrated by this case justifies the continuous use of G-CSF, although the lack of long-term perspectives should not be forgotten.
de Diego Fernández
P
P
Servicio de Pediatría, Hospital General Básico de Baza, Granada, Servicio Andaluz de Salud, Spain. pdediego@eresmas.com
García Fernández
J R
JR
Moreno Madrid
F
F
Sánchez Forte
M
M
D002675:Child, Preschool; D005260:Female; D005953:Glycogen Storage Disease Type I / Q000150:complications*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology
D016179:Granulocyte Colony-Stimulating Factor